|
|
Article: Endovasc Announces Plans to Bypass Phase II Liprostin Clinical Trials and Proceed to Phase III.
- Article from:
- Business Wire
- Article date:
- May 7, 2001
CopyrightCOPYRIGHT 2001 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health & Medical Writers
BIOWIRE2K
MONTGOMERY, Texas--(BW HealthWire)--May 7, 2001
Endovasc Ltd. Inc. (OTCBB:ENDV) today announced plans to move directly into Phase III human trials with Critical Limb Ischemic patients.
Having demonstrated very successful results from the recently concluded animal studies as well as a significant safety profile in Phase I human trials in healthy volunteers, Endovasc Ltd. Inc. has determined it will proceed with Phase III, i.e., the last phase of IND clinical development, as recommended by the Food and Drug Administration at their October 1999 Pre-Investigational New Drug Application ...